| Literature DB >> 28440406 |
Guang-Jian Liu1, Jian-Rong He1, Ya-Shu Kuang1, Xue-Jiao Fan1, Wei-Dong Li1, Jin-Hua Lu1, Xiao-Yan Xia1, Xiao-Dan Liu1, Nian-Nian Chen1, Wei-Bi Mai2, Hui-Min Xia1, Xiu Qiu1.
Abstract
Preterm birth is the leading cause of mortality and morbidity in infants. Its etiology is multifactorial with genes and immune homeostasis. The authors investigated whether prostaglandin (PG) synthesis related single nucleotide polymorphisms (SNPs) PLA2G4C rs1366442 and PLA2G4D rs4924618 were associated with the risk of spontaneous preterm birth (SPTB) in a Chinese population of 114 cases of SPTB and 250 controls of term delivery. The risk associations were determined by odds ratios (ORs) and their 95% confidence intervals (CIs) calculated using multivariate logistic regression. Homology modeling was performed to elucidate potential mechanism of the SNP function. The maternal AT/TT genotype of PLA2G4D rs4924618 was associated with a reduced risk of SPTB (OR, 0.61; 95% CI, 0.37‑0.99), while no significant association between PLA2G4C rs1366442 and SPTB risk was identified. Structure and sequence analysis revealed that the amino acid substitution introduced by this SNP located at the conserved central core of the catalytic domain of cytosolic phospholipase A2 δ and was close to the active site. These findings suggested that the polymorphism of PLA2G4D rs4924618 may have a protective influence on the SPTB susceptibility in a Chinese population, supporting a role for genetics in the association between PG synthesis and preterm birth.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28440406 PMCID: PMC5436275 DOI: 10.3892/mmr.2017.6475
Source DB: PubMed Journal: Mol Med Rep ISSN: 1791-2997 Impact factor: 2.952
Characteristics of participants.
| A, Mother | |||
|---|---|---|---|
| Characteristics | Cases, n (%) | Controls, n (%) | P-value |
| Age (years) | |||
| <30 | 55 (48.3) | 127 (50.8) | |
| ≥30 | 59 (51.8) | 123 (49.2) | 0.65 |
| Mean (SD) | 29.8 (3.5) | 29.8 (3.5) | 0.97 |
| Educational level | |||
| High middle school or below | 12 (10.5) | 36 (14.4) | 0.31 |
| College or above | 102 (89.5) | 214 (85.6) | |
| Marital Status | |||
| Unmarried | 0 (0.0) | 2 (0.8) | >0.99# |
| Married | 114 (100) | 248 (99.2) | |
| Parity | |||
| Primiparous | 92 (80.7) | 225 (90.0) | 0.01 |
| Multiparous | 22 (19.3) | 25 (10.0) | |
| History of abortion | |||
| Yes | 73 (76.8) | 149 (73.0) | 0.48 |
| No | 22 (23.2) | 55 (27.0) | |
| No data | 19 | 46 | |
| Previous history of preterm delivery | |||
| No | 94 (100.0) | 205 (99.0) | >0.99# |
| Yes | 0 (0.0) | 2 (1.0) | |
| No data | 20 | 43 | |
| Pre-pregnancy BMI | |||
| <20 | 74 (64.9) | 169 (67.6) | 0.61 |
| ≥20 | 40 (35.1) | 81 (32.4) | |
| Mean (SD) | 20.0 (2.1) | 19.8 (2.1) | 0.53 |
| Smoking | |||
| No | 67 (100.0) | 152 (99.4) | >0.99# |
| Yes | 0 (0.0) | 1 (0.7) | |
| No data | 47 | 97 | |
| GDM | |||
| No | 88 (77.2) | 201 (80.4) | 0.48 |
| Yes | 26 (22.8) | 49 (19.6) | |
| B, Newborn | |||
| Characteristics | Cases, n (%) | Controls, n (%) | P-value |
| Sex | |||
| Female | 46 (40.4) | 145 (58.0) | |
| Male | 68 (59.7) | 105 (42.0) | 0.002 |
| Birth weight (g), median (25th, 75th) | 2660 (2300, 2880) | 3280 (3030,3540) | <0.001 |
| Gestational age (weeks), median (25th, 75th) | 36 (35,36) | 39 (39,40) | <0.001 |
P-values indicate comparisons between the different subgroups of each characteristic. #Fisher exact test. SD, standard deviation; BMI, body mass index; GDM, gestational diabetes mellitus.
Associations of genetic variants with the risk of SPTB.
| Genotype | Controls, n (%) | Cases, n (%) | OR (95% CI)[ | OR (95% CI)[ |
|---|---|---|---|---|
| PLA2G4C rs1366442 | ||||
| CC | 159 (64.4) | 76 (67.3) | 1.00 (reference) | 1.00 (reference) |
| CA | 80 (32.4) | 34 (30.1) | 0.89 (0.55, 1.45) | 0.90 (0.54, 1.49) |
| AA | 8 (3.2) | 3 (2.7) | 0.79 (0.2, 3.04) | 1.06 (0.26, 4.24) |
| CA/AA | 88 (35.6) | 37 (32.7) | 0.88 (0.55, 1.41) | 0.91 (0.56, 1.49) |
| PLA2G4D rs4924618 | ||||
| AA | 66 (26.9) | 42 (36.8) | 1.00 (reference) | 1.00 (reference) |
| AT | 133 (54.3) | 57 (50.0) | 0.67 (0.41, 1.11) | 0.65 (0.38, 1.09) |
| TT | 46 (18.8) | 15 (13.2) | 0.51 (0.26, 1.03) | 0.50 (0.24, 1.02) |
| AT/TT | 179 (73.1) | 72 (63.2) | 0.63 (0.39, 1.02) | 0.61 (0.37, 0.99) |
OR and 95% CI are presented relative to the reference group in each section.
Crude OR and 95% CI.
Adjusted for maternal age, educational level, parity, pre-pregnancy BMI, status of GDM and infant sex. SPTB, spontaneous preterm birth; OR, Odds ratio; CI, confidence interval; BMI, body mass index; GDM, gestational diabetes mellitus.
Stratified analysis for associations between PLA2G4C and PLA2G4D variants and the risk of SPTB.
| PLA2G4C rs1366442 | PLA2G4D rs4924618 | |||||
|---|---|---|---|---|---|---|
| Stratified variables | Genotype | Case/Control, n | OR (95% CI)[ | Genotype | Case/Control, n | OR (95% CI)[ |
| Age | ||||||
| <30 | CC | 34/83 | 1.00 (reference) | AA | 16/35 | 1.00 (reference) |
| CA/AA | 20/43 | 1.13 (0.56, 2.28) | AT/TT | 39/89 | 0.83 (0.39, 1.8) | |
| ≥30 | CC | 42/76 | 1.00 (reference) | AA | 26/31 | 1.00 (reference) |
| CA/AA | 17/45 | 0.75 (0.37, 1.51) | AT/TT | 33/90 | 0.42 (0.21, 0.83) | |
| P-value for interaction | 0.33 | 0.10 | ||||
| GDM | ||||||
| No | CC | 60/132 | 1.00 (reference) | AA | 32/52 | 1.00 (reference) |
| CA/AA | 27/66 | 1.02 (0.58, 1.79) | AT/TT | 56/144 | 0.59 (0.34, 1.04) | |
| Yes | CC | 16/27 | 1.00 (reference) | AA | 10/14 | 1.00 (reference) |
| CA/AA | 10/22 | 0.50 (0.17, 1.52) | AT/TT | 16/35 | 0.68 (0.22, 2.08) | |
| P-value for interaction | 0.43 | 0.06 | ||||
| Sex | ||||||
| Female | CC | 46/71 | 1.00 (reference) | AA | 27/27 | 1.00 (reference) |
| CA/AA | 21/31 | 1.10 (0.55, 2.21) | AT/TT | 41/75 | 0.47 (0.23, 0.94) | |
| Male | CC | 30/88 | 1.00 (reference) | AA | 15/39 | 1.00 (reference) |
| CA/AA | 16/57 | 0.81 (0.40, 1.64) | AT/TT | 31/104 | 0.76 (0.36, 1.59) | |
| P-value for interaction | 0.67 | 0.31 | ||||
OR and 95% CI are presented relative to the reference group in each section.
Adjusted for maternal age, educational level, parity, pre-pregnancy BMI, status of GDM and infant sex. OR, Odds ratio; CI, confidence interval; BMI, body mass index; GDM, gestational diabetes mellitus.
Figure 1.Tertiary structure of cPLA2 δ. (A) Predictive 3D model aligned to the template (red, template; yellow and cyan, model). (B) Location of the mutation site and active site in cPLA2 δ. The central core is presented in yellow, with the secondary structure elements labeled according to the crystal structure of cPLA2 α. The cap region is colored blue. The mutation site Ser434 and active site Ser361 are displayed as green spheres. Side chains of residues constituting the active site funnel are displayed as colored sticks with black type. This image was made with VMD software support. VMD is developed with NIH support by the Theoretical and Computational Biophysics group at the Beckman Institute, University of Illinois at Urbana-Champaign (Champaign, IL, USA). cPLA2, cytosolic phospholipase A2.
Figure 2.Ramachandran plot of a structural model of cPLA2δ. The most energetically allowed regions of Ramachandran space is colored blue and the allowed regions are colored green. This image was made with VMD software support. VMD is developed with NIH support by the Theoretical and Computational Biophysics group at the Beckman Institute, University of Illinois at Urbana-Champaign (Champaign, IL, USA). cPLA2, cytosolic phospholipase A2.
Figure 3.Primary structure alignment of cPLA2 α, β, γ and δ. Plot of the secondary structure observed in the X-ray crystal structure of cPLA2 α is labeled below the sequences and the central core is colored yellow and purple. Residues indicated with dotted lines are not included in the X-ray structure. The asterisks identify residues lining the active site. cPLA2, cytosolic phospholipase A2.